Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

December 9, 2020December 9, 2020

Vitamin D Supplements Could Have Potential as XLH Therapy, Mouse Study Shows

News

Vitamin D dietary supplements can promote bone mineralization without changing phosphate levels or causing calcium to rise to unhealthy levels and form solid deposits in the kidneys. That finding, from ... Read more

September 3, 2020September 3, 2020

IOF $1K Awards Focus on XLH, Other Rare Skeletal Diseases

News

The International Osteoporosis Foundation (IOF) has given its first five Skeletal Rare Diseases Academy Awards to researchers working on rare bone disorders, including X‐linked hypophosphatemia (XLH). Selected by a panel ... Read more

July 16, 2020July 16, 2020

Safer, More Effective Therapies Needed for Hypophosphatemic Rickets, Turkish Study Reports

News

Higher doses of phosphate and vitamin D supplements seem to reduce bone deformities in young people with hypophosphatemic rickets (HR), a Turkish nationwide study reports. However, such increased doses also ... Read more

April 15, 2020April 15, 2020

Early XLH Identification, Treatment Crucial to Keeping Quality of Life

News

Identifying and treating X‐linked hypophosphatemia (XLH) early is key to improving quality of life for people with the disorder, particularly in developing countries, a case report shows. The report, detailing a ... Read more

January 15, 2020January 15, 2020

A Third of Youngsters with XLH are Overweight or Obese, Study Finds

News

Approximately one third of children and young adults with X‐linked hypophosphatemia (XLH) are overweight or obese, a study has found. Lack of family history of XLH and longer treatment with ... Read more

December 11, 2019December 11, 2019

Crysvita Restores Phosphate Balance, Improves Bone Health in Adults With XLH, Phase 3 Trial Shows

News

Treatment with Crysvita (burosumab) restores phosphate balance and improves bone mineralization in adults with X‐linked hypophosphatemia (XLH), a Phase 3 trial shows. The findings were reported in a study, “Burosumab Improved ... Read more